Skip to content

Clinical study of Jianpi Liqi Huashi Decoction on insulin resistance and free fatty acid in nonalcoholic steatohepatitis in patients

Clinical study of Jianpi Liqi Huashi Decoction on insulin resistance and free fatty acid in nonalcoholic steatohepatitis in patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-14005445
Enrollment
Unknown
Registered
2014-10-30
Start date
2014-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic steatohepatitis

Interventions

Jianpi Liqi Huashi decoction Group:Jianpi Liqi Huashi decoction
Control group:Placebo (1/10 dosage Jianpi Liqi Huashi decoction)

Sponsors

Infectious Disease Hospital of Pudong New Area Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) NASH patients is diagnosed by B ultrasound and liver function tests; 2) Spleen-deficiency and dampness-heat syndrome is diagnosed by TCM syndrome differentiation standard; 3) Age is between 18 to 65 years old; 4) Patients did not participate in the similar clinical trial 2 weeks ago; 5) Volunteered to participate in this study; 6) Informed consent must be signed.

Exclusion criteria

Exclusion criteria: 1) Combined with drug-induced liver injury, autoimmune hepatitis, viral hepatitis; 2) Combined with heart, brain, kidney, lung, blood, diabetes, thyroid dysfunction, metabolic and gastrointestinal diseases, or psychiatric patients; 3) Lactation, pregnancy or preparing to pregnant women; 4) Liver function values greater than 2.5 times the upper limit of normal, creatinine greater than the upper limit of normal values; 5) Using drugs to lose weight; 6) in critical condition, it is difficult to make a precise evaluation of drug efficacy and safety etc.; 7) allergic constitution and the medicine or the prescription composition of allergy; 8) Participate in other clinical trials; 9) Taking other drugs or therapy related to the treatment of this disease in 2 weeks; 10) patients not willing to cooperateare.

Design outcomes

Primary

MeasureTime frame
Body mass index;Waist to hip Ratio;Symptoms and signs scores;Liver function;Blood glucose;Free fatty acid;Blood lipid;Ultrasound B;Vital signs;Blood routine;Urine routine;Stool routine;Kidney function;

Countries

China

Contacts

Public ContactYang Cheng
drchengyang@126.com+86 13817231670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026